Table 3 Differences before and after 6- months of biological drug therapy

Exacerbations

2.87 ± 0.68

0.27 ± 0.45

< 0.001

2.95 ± 0.79

0.27 ± 0.55

< 0.001

ACT

11.2 ± 2.6

19.6 ± 2.3

< 0.001

12.2 ± 1.9

19.2 ± 2.0

< 0.001

Spirometric values (M ± SD)

 FEV₁ (L)

2.28 ± 0.52

2.80 ± 0.65

< 0.001

1.93 ± 0.72

2.30 ± 0.81

< 0.001

 FEV₁ (%)

72 ± 12

87 ± 13

< 0.001

72 ± 14

86 ± 14

< 0.001

 FVC (L)

3.72 ± 0.95

4.03 ± 1.05

0.002

3.05 ± 1.15

3.30 ± 1.17

0.001

 FVC%

92 ± 11

101 ± 11

< 0.001

90 ± 13

98 ± 14

0.002

 FEV₁/FVC

62 ± 11

71 ± 8

< 0.001

64 ± 9

70 ± 8

< 0.001

FeNO (ppb)

29 ± 7

21 ± 3

< 0.001

26.7 ± 2.5

20.2 ± 2.2

< 0.001

Eosinophils (n/μL)

457 ± 193

181 ± 258

< 0.001

483 ± 24

200 ± 235

0.002

Eosinophils %

5.7 ± 2.8

2.2 ± 3.2

< 0.001

5.96 ± 2.81

2.28 ± 2.67

< 0.001

PCS 12

36 ± 9

47 ± 9

< 0.001

32 ± 8

46 ± 8

< 0.001

MCS 12

47 ± 8

52 ± 7

< 0.001

44 ± 11

51 ± 6

0.003

WAI

34 ± 6

40 ± 6

< 0.001

Absenteeism (%)

19 ± 15

3 ± 11

< 0.001

Presenteeism (%)

53 ± 24

29 ± 26

< 0.001

Overall work impairment (%)

57 ± 25

29 ± 27

< 0.001

Impact on daily activities (%)

41 ± 23

21 ± 21

< 0.001

65 ± 21

40 ± 26

< 0.001